FocalTherics (NASDAQ:FOCL) Director David Horn Purchases 10,000 Shares

FocalTherics (NASDAQ:FOCL) Director David Horn bought 10,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the purchase, the director owned 10,000 shares of the company’s stock, valued at $47,500. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

FocalTherics Stock Down 8.4%

NASDAQ:FOCL opened at $4.36 on Tuesday. The firm has a market capitalization of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The business has a 50-day simple moving average of $5.38.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The company had revenue of $13.20 million for the quarter. On average, research analysts expect that FocalTherics will post -0.78 EPS for the current year.

Analysts Set New Price Targets

FOCL has been the topic of a number of analyst reports. Mizuho set a $15.00 price target on FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a report on Tuesday, June 2nd. Piper Sandler restated a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a research note on Friday. Finally, Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, FocalTherics has an average rating of “Hold” and an average price target of $7.75.

FocalTherics News Roundup

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

Hedge Funds Weigh In On FocalTherics

Several institutional investors have recently bought and sold shares of FOCL. SmartHarvest Portfolios LLC acquired a new position in FocalTherics in the first quarter worth $38,000. Lido Advisors LLC acquired a new stake in shares of FocalTherics in the first quarter valued at $40,000. Kovack Advisors Inc. acquired a new stake in shares of FocalTherics in the fourth quarter valued at $53,000. Rock Springs Capital Management LP raised its holdings in shares of FocalTherics by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after buying an additional 16,500 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in shares of FocalTherics in the fourth quarter valued at about $313,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.